Guideline

Guidelines for the Treatment of Malaria

Year of Publication

2010

Issuing Institution

Links

Recommendations

6 included recommendations

Artemisinin-based combination therapies should be used in preference to sulfadoxinepyrimethamine (SP) plus amodiaquine (AQ) for the treatment of uncomplicated P. falciparum malaria.

Status

New

Recommended in favor

Strong

Certainty of evidence

Moderate

Artemisinin-based combination therapies (ACTs) should include at least 3 days of treatment with an artemisinin derivative.

Status

Maintained

Recommended in favor

Strong

Certainty of evidence

High

Dihydroartemisinin plus piperaquine (DHA+PPQ) is an option for the first-line treatment of uncomplicated P. falciparum malaria worldwide.

Status

Retired

Recommended in favor

Strong

Certainty of evidence

High

Intravenous (IV) artesunate should be used in preference to quinine for the treatment of severe P.falciparum malaria in adults

Status

New

Recommended in favor

Strong

Certainty of evidence

High

In areas with chloroquine resistant P. vivax, artemisinin-based combination therapies (particularly those whose partner medicines have long half-lives) are recommended for the treatment of P. vivax malaria.

Status

New

Recommended in favor

Conditional

Certainty of evidence

Moderate

At least a 14-day course of primaquine is required for the radical treatment of P. vivax

Status

New

Recommended in favor

Strong

Certainty of evidence

Very low